SMART-NeuroDx is reported, a reagent-free electrochemical array that quantifies pTau217, GFAP, pTau181, and NfL directly from unprocessed plasma and serum in under 35 minutes, establishing reagent-free, simultaneous four-analyte neurodegeneration sensing on a single point-of-care device.
Abstract
Differentiating overlapping dementia pathologies, such as frontotemporal dementia and Alzheimer’s disease, calls for the simultaneous measurement of several blood biomarkers, yet electrochemical sensors remain predominantly single-target and dependent on labels and sample preparation. Here we report SMART-NeuroDx, a reagent-free electrochemical array that quantifies pTau217, GFAP, pTau181, and NfL directly from unprocessed plasma and serum in under 35 minutes. Four surface-confined redox-active molecularly imprinted polymer and aptamer-MIP recognition matrices are electropolymerized onto a four-working-electrode porous-gold printed-circuit array, using potential-assisted electrostatic gating keyed to each target’s isoelectric point to prevent cross-channel template contamination during synthesis. Label-free Faradaic responses from the redox-active polymer backbone are acquired on a custom battery-powered STM32G4 handheld potentiostat and converted to concentration from five voltammetric features using cross-validated Random Forest and XGBoost regressors. The handheld unit reproduced the baseline fidelity of a commercial benchtop workstation and resolved sub-picogram pTau217 (limit of detection 0.087 pg mL⁻¹) across marker-appropriate dynamic ranges, with inter-chip relative standard deviation at or below 5.34% and coefficients of determination of 0.94 to 0.99 against reference concentrations. Each channel retained selectivity in plasma and serum against competing neurological and inflammatory proteins, with non-specific signal deviation held below 10% by the hydrated PyPEG interfacial shell. The platform establishes reagent-free, simultaneous four-analyte neurodegeneration sensing on a single point-of-care device.
Alzheimer’s disease (AD) diagnostic workflows are undergoing a paradigm shift from symptom-centric cognitive assessment to biomarker-guided pathological stratification, fuelling an urgent need for minimally invasive analytical tools to quantify ultralow-concentration pathological markers within peripheral biofluids. Bi...
Jiao Wang, Zi-Jin Wei, Zian Zhao et al.· Biosensing and Biomedicine· 0 citations
A review examines the potential of nanomaterial-based sensing strategies for developing clinically relevant neurodiagnostics, categorizes them systematically, and links them to biomarker profiles for AD and PD.
Shajahan Azeez, Raj Kumar Chinnadurai, Saravanaraman Ponne et al.· International review of neur...· 0 citations
Alzheimer's disease (AD) and Parkinson's disease (PD) are considered among the most difficult neurodegenerative diseases because they are progressive, and there are no reliable tools to make early diagnoses. Traditional diagnostic approaches, such as neuroimaging and CSF analysis, are not ideal for rapid clinical scree...
Muhammad Waqas Usmani, Abdur Rahim, Faiza Farid et al.· Talanta: The International J...· 0 citations
Traumatic brain injury (TBI) affects an estimated 69 million people each year and remains difficult to diagnose rapidly because conventional assessment relies heavily on neurological examination and computed tomography, which may miss subtle injuries or be unavailable in many clinical settings. Blood-based biomarkers,...
Jacob Wekalao, Tobias Topisia· Frontiers in Neurology· 0 citations
Point-of-care (PoC) facilities need nucleic-acid assays that can shorten turnaround time and simplify workflow while maintaining analytical performance in realistic matrices. We describe a materials-driven electrochemical platform based on floating catalyst chemical vapor deposition-synthesized continuous carbon...
Eero Gustafsson, Samuel Rantataro, Jane Besong-Ndika et al.· Clinical Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.